Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00296010
Registration number
NCT00296010
Ethics application status
Date submitted
23/02/2006
Date registered
24/02/2006
Date last updated
23/02/2021
Titles & IDs
Public title
Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
Query!
Scientific title
Phase III Trial Evaluating the Role of Adjuvant Pegylated Liposomal Doxorubicin (PLD, Caelyx, Doxil) for Women (Age 66 Years or Older) With Endocrine Nonresponsive Breast Cancer Who Are Not Suitable for Being Offered a " Standard Chemotherapy Regimen"
Query!
Secondary ID [1]
0
0
IBCSG-32-05
Query!
Secondary ID [2]
0
0
CDR0000463710
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
CASA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - cyclophosphamide
Treatment: Drugs - methotrexate
Treatment: Drugs - pegylated liposomal doxorubicin hydrochloride
Treatment: Surgery - adjuvant therapy
Treatment: Other - radiation therapy
Experimental: CASA-nil PLD - Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
Active Comparator: CASA-Nil - No adjuvant therapy
Experimental: CASA-CM PLD - Adjuvant pegylated liposomal doxorubicin (PLD) for 16 weeks
Active Comparator: CASA-CM CM - Low-dose, metronomic cyclophosphamide and methotrexate (CM) for 16 weeks
Treatment: Drugs: cyclophosphamide
cyclophosphamide 50 mg/day orally continuously for 16 weeks
Treatment: Drugs: methotrexate
methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
Treatment: Drugs: pegylated liposomal doxorubicin hydrochloride
Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
Treatment: Surgery: adjuvant therapy
Treatment: Other: radiation therapy
Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Surgery
Query!
Intervention code [3]
0
0
Treatment: Other
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Breast cancer free interval by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 years after recruitment starts
Query!
Secondary outcome [1]
0
0
Adverse events assessed by CTCAE v3.0 every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually after completion of study treatment
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
5 years after recruitment starts
Query!
Secondary outcome [2]
0
0
Quality of life assessed by Casa QL form, Mini-Cog, and VES-13 at baseline and at 2, 6, and 12 months after completion of study treatment
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
5 years after recruitment starts
Query!
Secondary outcome [3]
0
0
Disease-free survival by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
5 years after recruitment starts
Query!
Secondary outcome [4]
0
0
Overall survival by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
5 years after recruitment starts
Query!
Secondary outcome [5]
0
0
Sites of failure by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
5 years after recruitment starts
Query!
Secondary outcome [6]
0
0
Second (non-breast) malignancy by physical examination, laboratory tests, and investigations every 2 weeks for 16 weeks during treatment, every 3-6 months for 5 years, then annually as indicated after completion of study treatment
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
5 years after recruitment starts
Query!
Secondary outcome [7]
0
0
Causes of death prior to breast cancer recurrence by physical examination, laboratory tests, and investigations every 2 wks for 16 wks during treatment, every 3-6 mo. for 5 yrs, then annually as indicated after completion of study treatment
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
5 years after recruitment starts
Query!
Eligibility
Key inclusion criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed breast cancer
- Disease must be confined to the breast and axillary nodes without detected masses
elsewhere
- No history of prior ipsilateral or contralateral invasive breast cancer
- Resected disease
- No more than 16 weeks since last surgery to remove the tumor
- No known clinical residual locoregional disease
- Margins must be negative for invasive breast cancer and ductal carcinoma in situ
- No locally advanced, inoperable breast cancer including any of the following:
- Inflammatory breast cancer
- Supraclavicular node involvement
- Enlarged internal mammary nodes unless pathologically negative
- Synchronous bilateral invasive breast cancer (diagnosed in the past 2 months) allowed
if all tumors are hormone receptor-negative
- Must not be a candidate for endocrine therapy or standard chemotherapy
- Hormone receptor-negative disease
PATIENT CHARACTERISTICS:
- Female
- Menopausal status: postmenopausal
- ECOG performance status 0-2
- Platelet count = 100,000/mm^3
- Granulocyte count = 1,500/mm^3
- WBC = 3,000/mm^3
- AST and ALT = 1.5 times upper limit of normal (ULN)
- Bilirubin normal
- Creatinine clearance = 50 mL/min
- Creatinine < 1.35 mg/dL
- No significant malabsorption syndrome or disease affecting gastrointestinal tract
function
- No myocardial infarction within the past 6 months
- No pulmonary embolism within the past 6 months
- No deep vein thrombosis within the past 6 months
- No New York Heart Association class III or IV heart disease
- LVEF = 50% by echocardiography, radionucleotide ventriculography, or MUGA
- No evidence of acute ischemia by ECG
- No other malignancy within the past 5 years except adequately treated basal cell or
squamous cell skin cancer, carcinoma in situ of the cervix or bladder, or ipsilateral
or contralateral breast carcinoma in situ
- No active, uncontrolled infection
- No active hepatitis B or C virus infection
- No other chronic infection
- Patients must not have any of the following "geriatric syndromes":
- Dementia
- Delirium
- Major depression (as diagnosed by a psychiatrist)
- Recent falls
- Spontaneous bone fractures
- Neglect
- Abuse
- No evidence of medically relevant conduction system abnormalities that would preclude
study entry
- No other nonmalignant, uncontrolled systemic diseases, psychiatric illness, or
addictive or cognitive disorder that would preclude study participation or compliance
PRIOR CONCURRENT THERAPY:
- At least 4 weeks since prior raloxifene, tamoxifen citrate, or other selective
estrogen receptor modulators (SERMs)
- No concurrent recombinant human epoetin alfa or pegfilgrastim
- No prior neoadjuvant or adjuvant therapy for breast cancer except radiotherapy
- Concurrent trastuzumab (Herceptin®) allowed
- No concurrent hormonal replacement therapy
- No other concurrent hormonal therapy (including estrogen, progesterone, androgens,
tamoxifen citrate, SERMs, or aromatase inhibitors) except for the following:
- Steroids for adrenal failure
- Hormones for non-disease-related conditions (e.g., insulin for diabetes)
- Intermittent dexamethasone as an antiemetic
- No other concurrent investigational agents
- No concurrent bisphosphonates, except for the treatment of osteoporosis
- For patients who received prior anthracyclines, the following criteria must be met:
- Cumulative dose = 240 mg/m² for conventional doxorubicin
- = 140 mg/m² in case of prior doxorubicin and left chest radiotherapy (LCRT)
- Cumulative dose = 400 mg/m² for epirubicin
- = 230 mg/m² in case of prior epirubicin and LCRT
Query!
Minimum age
66
Years
Query!
Query!
Maximum age
120
Years
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/08/2005
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/12/2011
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
77
Query!
Recruitment in Australia
Recruitment state(s)
NSW,TAS,VIC
Query!
Recruitment hospital [1]
0
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [2]
0
0
Nepean Cancer Care Centre at Nepean Hospital - Kingswood
Query!
Recruitment hospital [3]
0
0
Royal Hobart Hospital - Hobart
Query!
Recruitment hospital [4]
0
0
Frankston Hospital - Frankston
Query!
Recruitment postcode(s) [1]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [2]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [3]
0
0
7000 - Hobart
Query!
Recruitment postcode(s) [4]
0
0
3199 - Frankston
Query!
Recruitment outside Australia
Country [1]
0
0
Belgium
Query!
State/province [1]
0
0
Brussels
Query!
Country [2]
0
0
Belgium
Query!
State/province [2]
0
0
Kortrijk
Query!
Country [3]
0
0
Belgium
Query!
State/province [3]
0
0
Leuven
Query!
Country [4]
0
0
Belgium
Query!
State/province [4]
0
0
Liege
Query!
Country [5]
0
0
Hungary
Query!
State/province [5]
0
0
Budapest
Query!
Country [6]
0
0
Italy
Query!
State/province [6]
0
0
Aviano
Query!
Country [7]
0
0
Italy
Query!
State/province [7]
0
0
Bergamo
Query!
Country [8]
0
0
Italy
Query!
State/province [8]
0
0
Biella
Query!
Country [9]
0
0
Italy
Query!
State/province [9]
0
0
Carpi
Query!
Country [10]
0
0
Italy
Query!
State/province [10]
0
0
Fano
Query!
Country [11]
0
0
Italy
Query!
State/province [11]
0
0
Milano
Query!
Country [12]
0
0
Italy
Query!
State/province [12]
0
0
Rimini
Query!
Country [13]
0
0
Italy
Query!
State/province [13]
0
0
Rome
Query!
Country [14]
0
0
Italy
Query!
State/province [14]
0
0
Treste
Query!
Country [15]
0
0
Italy
Query!
State/province [15]
0
0
Udine
Query!
Country [16]
0
0
Italy
Query!
State/province [16]
0
0
Varese
Query!
Country [17]
0
0
New Zealand
Query!
State/province [17]
0
0
Auckland
Query!
Country [18]
0
0
Romania
Query!
State/province [18]
0
0
Cluj-Napoca
Query!
Country [19]
0
0
Slovenia
Query!
State/province [19]
0
0
Ljubljana
Query!
Country [20]
0
0
Sweden
Query!
State/province [20]
0
0
Gothenburg
Query!
Country [21]
0
0
Sweden
Query!
State/province [21]
0
0
Skovde
Query!
Country [22]
0
0
Switzerland
Query!
State/province [22]
0
0
Aarau
Query!
Country [23]
0
0
Switzerland
Query!
State/province [23]
0
0
Bern
Query!
Country [24]
0
0
Switzerland
Query!
State/province [24]
0
0
Chur
Query!
Country [25]
0
0
Switzerland
Query!
State/province [25]
0
0
Mendrisio
Query!
Country [26]
0
0
Switzerland
Query!
State/province [26]
0
0
St. Gallen
Query!
Country [27]
0
0
Switzerland
Query!
State/province [27]
0
0
Thun
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
ETOP IBCSG Partners Foundation
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, and liposomal
doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the
cells or by stopping them from dividing. Giving chemotherapy after surgery may kill any tumor
cells that remain after surgery. It is not yet known whether giving liposomal doxorubicin
after surgery is more effective than observation or cyclophosphamide and methotrexate in
treating breast cancer.
PURPOSE: This randomized phase III trial is studying liposomal doxorubicin to see how well it
works compared with observation or cyclophosphamide and methotrexate in treating older women
who have undergone surgery for breast cancer.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00296010
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Diana Crivellari, MD
Query!
Address
0
0
Centro di Riferimento Oncologico, Aviano (Italy)
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00296010
Download to PDF